Analysts see $3B potential in Sanofi-Regeneron cholesterol drug alirocumab

09/26/2013 | Reuters

Sanofi and Regeneron Pharmaceuticals' late-stage cholesterol therapy candidate alirocumab has the potential to become a blockbuster with more than $3 billion in sales, analysts said. Alirocumab belongs to a class of drugs called PCSK9 inhibitors. Deutsche Bank analysts said peak annual sales of alirocumab could reach exceed $3 billion, and BioMedTracker, an independent research firm, predicted sales of $3.7 billion by 2023.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN